HMI-115 is under clinical development by Hope Medicine and currently in Phase II for Endometriosis. According to GlobalData, Phase II drugs for Endometriosis have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HMI-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HMI-115 overview

HMI-115 (BAY-1158061) isunder development for the treatment of endometriosis and androgenic alopecia. It is a monoclonal antibody which acts by targeting prolactin receptor. Prolactin (PRL) receptor is a transmembrane receptor belonging to the class 1 cytokine receptor superfamily. It is administered through subcutaneous route.

Hope Medicine overview

Hope Medicine., is a biopharmaceutical company engaged in drug discovery and development services. The company is headquartered in China.

For a complete picture of HMI-115’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.